These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17505513)

  • 1. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade.
    Burger M; Denzinger S; Hartmann A; Wieland WF; Stoehr R; Obermann EC
    Br J Cancer; 2007 Jun; 96(11):1711-5. PubMed ID: 17505513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
    Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F
    Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
    Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
    J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. REG1A predicts recurrence in stage Ta/T1 bladder cancer.
    Geng J; Fan J; Wang P; Fang ZJ; Xia GW; Jiang HW; Chen G; Ding Q
    Eur J Surg Oncol; 2009 Aug; 35(8):852-7. PubMed ID: 19167858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma.
    Dudderidge TJ; Stoeber K; Loddo M; Atkinson G; Fanshawe T; Griffiths DF; Williams GH
    Clin Cancer Res; 2005 Apr; 11(7):2510-7. PubMed ID: 15814627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder.
    Krüger S; Thorns C; Stöcker W; Müller-Kunert E; Böhle A; Feller AC
    Eur Urol; 2003 Feb; 43(2):138-45. PubMed ID: 12565771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penis.
    May M; Burger M; Otto W; Hakenberg OW; Wieland WF; May D; Hofstädter F; Götz S; Niessl N; Fritsche HM; Birnkammer K; Gilfrich C; Peter J; Jain A; Koch S; Lebentrau S; Riedmiller H; Rössler W; Denzinger S; Brookman-May S; Gunia S
    BJU Int; 2013 Aug; 112(4):E383-90. PubMed ID: 23305250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
    Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
    Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder.
    Ramos D; Navarro S; Villamón R; Gil-Salom M; Llombart-Bosch A
    Cancer; 2003 Apr; 97(8):1876-83. PubMed ID: 12673713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
    Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
    Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
    van Rhijn BW; Liu L; Vis AN; Bostrom PJ; Zuiverloon TC; Fleshner NE; van der Aa MN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Bapat B; van der Kwast TH; Zlotta AR
    BJU Int; 2012 Oct; 110(8):1169-76. PubMed ID: 22448597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
    Barbisan F; Santinelli A; Mazzucchelli R; Lopez-Beltran A; Cheng L; Scarpelli M; van der Kwast T; Montironi R
    Cancer; 2008 Feb; 112(3):636-44. PubMed ID: 18072261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer?
    Gudjónsson S; Bendahl PO; Chebil G; Höglund M; Lindgren D; Lundberg LM; Lövgren K; Fernö M; Månsson W; Liedberg F
    Scand J Urol Nephrol; 2011 Sep; 45(4):270-7. PubMed ID: 21504385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.